Cargando…
Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343324/ https://www.ncbi.nlm.nih.gov/pubmed/28274265 http://dx.doi.org/10.1186/s13195-017-0245-y |
_version_ | 1782513345189904384 |
---|---|
author | Hesse, Raphael Lausser, Ludwig Gummert, Pauline Schmid, Florian Wahler, Anke Schnack, Cathrin Kroker, Katja S. Otto, Markus Tumani, Hayrettin Kestler, Hans A. Rosenbrock, Holger von Arnim, Christine A. F. |
author_facet | Hesse, Raphael Lausser, Ludwig Gummert, Pauline Schmid, Florian Wahler, Anke Schnack, Cathrin Kroker, Katja S. Otto, Markus Tumani, Hayrettin Kestler, Hans A. Rosenbrock, Holger von Arnim, Christine A. F. |
author_sort | Hesse, Raphael |
collection | PubMed |
description | BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as depression. The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are essential second messengers that play a crucial role in memory processing as well as synaptic plasticity and are potential therapeutic targets. Biomarkers that are able to monitor potential treatment effects and that reflect the underlying pathology are of crucial interest. METHODS: In this study, we measured cGMP and cAMP in cerebrospinal fluid (CSF) in a cohort of 133 subjects including 68 AD patients and 65 control subjects. To address the association with disease progression we correlated cognitive status with cyclic nucleotide levels. Because a high burden of NPSs is associated with decrease in cognitive function, we performed an exhaustive evaluation of AD-relevant marker combinations in a depressive subgroup. RESULTS: We show that cGMP, but not cAMP, levels in the CSF of AD patients are significantly reduced compared with the control group. Reduced cGMP levels in AD patients correlate with memory impairment based on Mini-Mental State Examination score (r = 0.17, p = 0.048) and tau as a marker of neurodegeneration (r = –0.28, p = 0.001). Moreover, we were able to show that AD patients suffering from current depression show reduced cGMP levels (p = 0.07) and exhibit a higher degree of cognitive impairment than non-depressed AD patients. CONCLUSION: These results provide further evidence for an involvement of cGMP in AD pathogenesis and accompanying co-morbidities, and may contribute to elucidating synaptic plasticity alterations during disease progression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-017-0245-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5343324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53433242017-03-10 Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression Hesse, Raphael Lausser, Ludwig Gummert, Pauline Schmid, Florian Wahler, Anke Schnack, Cathrin Kroker, Katja S. Otto, Markus Tumani, Hayrettin Kestler, Hans A. Rosenbrock, Holger von Arnim, Christine A. F. Alzheimers Res Ther Research BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as depression. The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are essential second messengers that play a crucial role in memory processing as well as synaptic plasticity and are potential therapeutic targets. Biomarkers that are able to monitor potential treatment effects and that reflect the underlying pathology are of crucial interest. METHODS: In this study, we measured cGMP and cAMP in cerebrospinal fluid (CSF) in a cohort of 133 subjects including 68 AD patients and 65 control subjects. To address the association with disease progression we correlated cognitive status with cyclic nucleotide levels. Because a high burden of NPSs is associated with decrease in cognitive function, we performed an exhaustive evaluation of AD-relevant marker combinations in a depressive subgroup. RESULTS: We show that cGMP, but not cAMP, levels in the CSF of AD patients are significantly reduced compared with the control group. Reduced cGMP levels in AD patients correlate with memory impairment based on Mini-Mental State Examination score (r = 0.17, p = 0.048) and tau as a marker of neurodegeneration (r = –0.28, p = 0.001). Moreover, we were able to show that AD patients suffering from current depression show reduced cGMP levels (p = 0.07) and exhibit a higher degree of cognitive impairment than non-depressed AD patients. CONCLUSION: These results provide further evidence for an involvement of cGMP in AD pathogenesis and accompanying co-morbidities, and may contribute to elucidating synaptic plasticity alterations during disease progression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-017-0245-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-09 /pmc/articles/PMC5343324/ /pubmed/28274265 http://dx.doi.org/10.1186/s13195-017-0245-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hesse, Raphael Lausser, Ludwig Gummert, Pauline Schmid, Florian Wahler, Anke Schnack, Cathrin Kroker, Katja S. Otto, Markus Tumani, Hayrettin Kestler, Hans A. Rosenbrock, Holger von Arnim, Christine A. F. Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression |
title | Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression |
title_full | Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression |
title_fullStr | Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression |
title_full_unstemmed | Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression |
title_short | Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression |
title_sort | reduced cgmp levels in csf of ad patients correlate with severity of dementia and current depression |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343324/ https://www.ncbi.nlm.nih.gov/pubmed/28274265 http://dx.doi.org/10.1186/s13195-017-0245-y |
work_keys_str_mv | AT hesseraphael reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT lausserludwig reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT gummertpauline reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT schmidflorian reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT wahleranke reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT schnackcathrin reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT krokerkatjas reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT ottomarkus reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT tumanihayrettin reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT kestlerhansa reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT rosenbrockholger reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression AT vonarnimchristineaf reducedcgmplevelsincsfofadpatientscorrelatewithseverityofdementiaandcurrentdepression |